Table 1 Pharmacokinetic and pharmacodynamic characteristics of oral factor Xa inhibitors

Oct 09, 2014

20 likes | 231 Views

Table 1 Pharmacokinetic and pharmacodynamic characteristics of oral factor Xa inhibitors. Cabral, K. P. & Ansell, J. (2012) Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation Nat. Rev. Cardiol. doi:10.1038/nrcardio.2012.19.

Share Presentation

Embed Code

Link

cardiol
pharmacodynamic characteristics
atrial fibrillation
stroke prevention
table 1 pharmacokinetic
oral factor xa inhibitors

devon

Download Presentation

Table 1 Pharmacokinetic and pharmacodynamic characteristics of oral factor Xa inhibitors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Table 1Pharmacokinetic and pharmacodynamic characteristics of oral factor Xa inhibitors Cabral, K. P. & Ansell, J. (2012)Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation Nat. Rev. Cardiol. doi:10.1038/nrcardio.2012.19

oral absorption, brain uptake pharmacokinetic and metabolic properties

A NEW IN-VITRO MODEL TO PREDICT THE IN VIVO BEHAVIOR OF DRUGS BASED ON PARALLEL ARTIFICIAL MEMBRANE AND PLASMA PROTEIN BINDING. Roberto Bozic October 27-29, 2008. INTRODUCTION. Plasma Protein Binding: is a reversible association of a drug with the proteins of the plasma compartment of blood.

654 views • 29 slides

Pharmacokinetic and Pharmacodynamic Studies for Systemic Exposure of Locally Acting Drugs

Pharmacokinetic and Pharmacodynamic Studies for Systemic Exposure of Locally Acting Drugs. Hartmut Derendorf, Ph.D. Günther Hochhaus, Ph.D. University of Florida. The Fate of Inhaled Corticosteroids. 10 - 40 % Deposited in lung. Complete absorption from the lung. Lung. Systemic

746 views • 39 slides

Pharmacokinetic and Pharmacodynamic Considerations in the Development of Macromolecules

Pharmacokinetic and Pharmacodynamic Considerations in the Development of Macromolecules. Pamela D. Garzone, Ph.D. OUTLINE OF LECTURE TOPICS. Macromolecules Interspecies Scaling Pharmacokinetic Characteristics Scientific Issues Pharmacodynamics Monoclonal Antibodies.

959 views • 51 slides

Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors

Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors. Brief Overview of NOACs. NOACs Important Comparative Features. Effect on NOAC Plasma Levels from D-D Interactions, and Recommendations. Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.

410 views • 26 slides

Bayesian Population Pharmacokinetic/Pharmacodynamic Modeling

Bayesian Population Pharmacokinetic/Pharmacodynamic Modeling. Steven Kathman GlaxoSmithKline. Half of the modern drugs could well be thrown out of the window, except that the birds might eat them. Dr. Martin Henry Fischer. Outline. Introduction Population PK modeling

769 views • 45 slides

Table 1 Selected characteristics of the HEMO and MPO study

Table 1 Selected characteristics of the HEMO and MPO study. Seabra V. F. et al. (2009) Some patients may benefit from using high-flux membranes Nat Rev Nephrol doi:10.1038/nrneph.2009.95.

230 views • 1 slides

Table 1. Characteristics and parameters of participants

Table 1. Characteristics and parameters of participants.

225 views • 4 slides

JGuiB - AN ASSISTANT TOOL FOR PHARMACOKINETIC/PHARMACODYNAMIC MODELING WORKING WITH BOOMER

JGuiB - AN ASSISTANT TOOL FOR PHARMACOKINETIC/PHARMACODYNAMIC MODELING WORKING WITH BOOMER. Ying-hao Lu 1 *, David W.A. Bourne 2 , Yung-jin Lee 1 1 College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan

169 views • 1 slides

The Value of Real Time Pharmacokinetic and Pharmacodynamic Modeling in Critical Care

The Value of Real Time Pharmacokinetic and Pharmacodynamic Modeling in Critical Care. Drug delivery devices. (V 3 ) Slow Peripheral Compartment. (V 2 ) Rapid Peripheral Compartment. (V 1 ) Central Compartment. Bar-coded Bolus Syringes. Pharmacokinetic Models. (V e ) Effect Site.

509 views • 35 slides

SMALL MOLECULE INHIBITORS OF ANTHRAX LETHAL FACTOR

SMALL MOLECULE INHIBITORS OF ANTHRAX LETHAL FACTOR. Phase I SBIR Project Period 7/01/05-6/30/07 P.I. Norton Peet John D. Williams. SPECIFIC AIMS. Optimize the in vitro LF inhibitory activity of the validated hit series Lead compound SAR Modeling/X-ray crystallography

347 views • 19 slides

Factor Inhibitors: Cases

Factor Inhibitors: Cases. Lisa N Boggio, MS, MD Rush University Medical Center. Case 1. 12-year-old patient with severe FVIII deficiency and inhibitor Normally treats bleeds with rFVIIa ~100 µg/kg Develops pain in arm. Case 1. Case 1. Case 1: Treatment.

412 views • 24 slides

Table 1 Pharmacokinetic properties of intravenous iron formulations

Table 1 Pharmacokinetic properties of intravenous iron formulations. B Michael et al. (2006) Drug Insight: safety of intravenous iron supplementation with sodium ferric gluconate complex. Nat Clin Pract Neprol 2: 9 2 – 100 doi:10.1038/ ncpneph0068.

244 views • 1 slides

Table 1. Patient Characteristics

Table 1. Patient Characteristics. Table 2. Overall Survival. EURTAC Preliminary Interim Analysis Results. Grade 3–4 Toxicities.

367 views • 4 slides

PHARMACOKINETIC

PHARMACOKINETIC. PHARMACOKINETICS. How long it takes for a drug to reach the blood circulation How long it takes for a drug to reach its site of action How long a drug stays at its site of action The dose needed to produce an adequate concentration of drug at its site of action

752 views • 27 slides

DIRECT FACTOR Xa INHIBITOR AS ANTICOAGULANT

For more presentations and information visit http://www.pharmaxchange.info. DIRECT FACTOR Xa INHIBITOR AS ANTICOAGULANT. PREET PAL SINGH SIDHU DEPT OF MEDICINAL CHEMISTRY SCHOOL OF PHARMACY, VCU. OVERVIEW. For more presentations and information visit http://www.pharmaxchange.info.

870 views • 37 slides

Table 1 Characteristics of intraparenchymal and extraparenchymal neurocysticercosis

Table 1 Characteristics of intraparenchymal and extraparenchymal neurocysticercosis. Nash, T. E. & Garcia, H. H. (2011) Diagnosis and treatment of neurocysticercosis Nat. Rev. Neurol. doi:10.1038/nrneurol.2011.135.

215 views • 1 slides

Table 1 Characteristics of neuroendocrine tumours

Table 1 Characteristics of neuroendocrine tumours. van Essen, M. et al. (2013) Neuroendocrine tumours: the role of imaging for diagnosis and therapy Nat. Rev. Endocrinol. doi:10.1038/nrendo.2013.246.

206 views • 1 slides

Blood Coagulation Factor Inhibitors

Blood Coagulation Factor Inhibitors-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Blood Coagulation Factor Inhibitors. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.

254 views • 7 slides

Supplementary Table 1. Immunological Characteristics of Patients

Supplementary Table 1. Immunological Characteristics of Patients.

96 views • 8 slides

Pharmacokinetic-pharmacodynamic integration in veterinary drug development: an overview

Pharmacokinetic-pharmacodynamic integration in veterinary drug development: an overview. NATIONAL VETERINARY S C H O O L T O U L O U S E. P.L. Toutain National Veterinary School ;Toulouse France EMEA : Focus group meeting on PK/PD London 24 September 2008. What is PK/PD?.

378 views • 35 slides

oral absorption, brain uptake pharmacokinetic and metabolic properties

308 views • 29 slides

More Related